ADVERTISEMENT
ADVERTISEMENT
Illustration of light blue neurons with white amyloid plaques accumulating on their axons.
New Alzheimer’s Drug Slows Cognitive Decline in Clinical Trial
The Biogen-developed treatment, called lecanemab, appears to have a more clear-cut effect on slowing the disease than the company’s previous Alzheimer’s drug, Aduhelm.
New Alzheimer’s Drug Slows Cognitive Decline in Clinical Trial
New Alzheimer’s Drug Slows Cognitive Decline in Clinical Trial

The Biogen-developed treatment, called lecanemab, appears to have a more clear-cut effect on slowing the disease than the company’s previous Alzheimer’s drug, Aduhelm.

The Biogen-developed treatment, called lecanemab, appears to have a more clear-cut effect on slowing the disease than the company’s previous Alzheimer’s drug, Aduhelm.

biogen

Updated
Photograph of the US Food and Drug Administration’s sign outside their offices in Washington, D.C.
Lawmakers Request Information About Alzheimer’s Drug Approval
Annie Melchor | Sep 3, 2021 | 3 min read
The FDA granted the drug, called Aduhelm, accelerated approval earlier this summer in a process that’s since drawn scrutiny.
Conference Linked to as Many as 300,000 COVID-19 Cases: Study
Lisa Winter | Dec 14, 2020 | 2 min read
Around 100 people were infected at a scientific meeting hosted by Biogen in Boston in February. Then they went back home, taking the virus with them.
COVID-19, SARS-CoV-2, coronavirus, pandemic, transmission, superspread, genome, virus, tracking, Biogen, Massachusetts
Thousands of Coronavirus Infections Stemmed from a Biotech Event
Amanda Heidt | Aug 26, 2020 | 3 min read
Officials had initially linked 97 cases to a single conference held by Biogen in February in Boston, but a new study tracking viral genomes suggests the number may be as high as 20,000.
biogen biobank coronavirus covid-19 sars-cov-2 pandemic superspreader superspreading event antibodies neutralizing titers
Biogen Uses its Own Superspreader Event to Aid COVID-19 Research
Claire Jarvis | May 19, 2020 | 3 min read
A blood biobank allows scientists to study the immune responses to the coronavirus among infected Biogen employees and their contacts.
ADVERTISEMENT